When the Breakthrough Obesity G-Agonist Drugs Exceed Expectations The expanding GLP-1 family of drugs and their expanded potential use cases Back last December I wrote about the The New Obesity Breakthrough Drugs, and specifically the striking results in randomized trials for semaglutide (Wegovy) and tirzepatide (Mounjaro) for weight loss, their putative mechanism(s), while also emphasizing their very high cost, lack of plan for successful weaning, and exacerbation of health inequities
Because it targets both GIP and GLP-1 receptors, I felt full faster and stayed full longer
Nutrients 12, 3135 (2020)
Additionally, Mihir Taneja has not been associated with Belcher/BPI as an employee, owner or officer for over five years. Before his sentencing, Taneja was the CEO of a health care firm called GeoPharma Inc., which traded under the ticker GORX and was then the parent company of Belcher
We've noticed remarkable transformations in our patients who select one of these treatments to help them start and maintain a healthy weight loss journey
doi:10.1016/j.tem.2020.02.006 Nauck MA, Meier JJ
